Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial

FRANKFURT (Reuters) - Germany's Merck KGaA suffered a setback in the development of key cancer immunotherapy Bavencio, which failed to prolong lives in gastric cancer patients when compared with standard chemotherapy.